Fairvalue-Calculator Fairvalue-Calculator
EN DE

Savior Lifetec Corporation (4167) Fair Value & Analysis

Healthcare · TW · Market cap 6.2B TWD

Price19.10 TWD
Fair Value15.71 TWD
Upside-17.7%
Quality95/100
Evidence: High Range 12.23 TWD – 18.98 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Savior Lifetec Corporation (4167) currently trades at 19.10 TWD, while our model-based Fair Value estimate is 15.71 TWD — implying the stock looks roughly 17.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Savior Lifetec Corporation engages in the research, development, design, manufacture, and sale of carbapenem generics in the Americas, Asia, Taiwan, Europe, and internationally. The company offers injection generics, controlled-release generics, the development of new dosage forms and drugs, and the APIs, excipients, intermediates, and dosage forms. It also provides medicine manufacturer technology and services. In addition, the company sells antibacterial raw materials and injectables. Savior Lifetec Corporation was founded in 1993 and is headquartered in Tainan City, Taiwan.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Savior Lifetec Corporation (4167) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 15.71 TWD versus a price of 19.10 TWD — about −18% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 4167?
Our 21-model fair value for Savior Lifetec Corporation is 15.71 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 19.10 TWD.
What is the quality score of 4167?
Savior Lifetec Corporation has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.